Tirzepatide (Mounjaro, Zepbound)
Tirzepatide (LY3298176)
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved once-weekly injection (Mounjaro for type 2 diabetes, Zepbound for weight loss) that activates two natural gut hormone pathways at once for more powerful blood sugar control and weight loss than older, single-pathway medications. Clinical trials show it produces greater weight loss than semaglutide.
Safety Summary
GI adverse events are the primary dose-limiting toxicities and most common reason for discontinuation (~10% at 15 mg). Incidence is dose-dependent: pooled GI AE rates ~39% at 5 mg, ~46% at 10 mg, ~49% at 15 mg. GI symptoms typically improve with time and slow titration. Severe GI events can lead to dehydration and acute kidney injury. Thyroid C-cell tumor boxed warning (rodent finding, human relevance unknown). No evidence of clinically meaningful tolerance/tachyphylaxis through 104 weeks of follow-up. Weight regain occurs upon discontinuation (~5.63 kg average in obesity populations). Anti-tirzepatide antibodies detected in some patients but with minimal impact on PK/efficacy per Phase 3 analysis.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-6]